INCONTINENCIA URINARIA

1. The Sifo Group in collaboration with pharmacia & Upjohn. Data on file, 1998.

2. National Association for Incontinence: Consumer Focus, 1996.

3. Abrams P, Wein AJ. The overactive bladder, A widespread but treatable condition. Stockholm: Erik Sparre Medical AB, 1998.

4. Brocklehurst JC. Urinary incontinence in the community- analysis of MORI poll. BMJ 1993;306:832- 834.

5. Ashworth PD, Haga MT. The meanig of incontinence: a quelitative study of non-geriatrc urinary incontinencesufferers. J Adv Nurs 1993; 18:1415-1423.

6. Lenderking WR, Nackley JF, Anderson RB et al. A review of the quality-oflife aspects of urinary urge incontinence, PharmacoEconomics 1996;9 11-23.

7. Fonda D, Woodward M, D´Astoli M, Fong Chin W. Sustained improvenment of sbjetive quality of life in older community dwelling people after treadment of urinary incontinence. Age Ageing 1995; 24 283-286.

8. Kelleger CJ, Cardozo LD, Toozs-Hobson PM. Quality of life and urinary incontinence. Curr Opin Obstet Gynecol 1995; 7: 404-408.

9. Kobelt- Nguyen G; Johannesson M, Mattiasson A, Abrams P. Correlations betwn symptoms of urge incontinence and score of and generic quality life instrument (SF36) and health status measurements (EuroQol) and betweeg changes in symptoms and qol score. Abstract presenten at the 27^th Annual Meeting of the International Continence Society, Yocohama, Japan, 23-27 September 19997.

10. Kamaroff AL, Fagioli LR, Doolitle TH et al. Health status in pacients with chronic fatigue syndrome and in general population and disease comparison groups. Am J Med 1996; 101: 281-290.

11. Joannesson M, O´Conor RM, Kobelt-Nguyen G, Mattiasson A. Willingness to pay for reduced incontinence problems. Br J Urol 1997; 80: 557-0562.

12. Anderson K-E Current concepts in the treatmen of disorders of micturition. Drugs 1988 35: 477-494.

13. Wenin AJ, Lonhurs PA, Levin RM. Pharmacologic treatmet of voiding dysfuntion. In : Mundy AR, Stepheson TP, Wein AJ (eds). Urodinamics : principles, practice and aplication. 2^nd Edition. New York: Churchill Livingstone, 1994: 43-70.

14. Baigrie RJ, Keller JP, Faucett DP, Pengelly AW. Oxibutynin: is itsafe? Br J Urol 1998; 62:319-322.

15. Yarker YE, Goa KL, Fitton A. Oxibutynin. A review of is pharmacodynamic and pharmacokinetic propierties, and its therapeutic use in detrusor instability. Drugs Agig 1995; 6: 243-262.

16. Lelleher CJ, Cardozo LD, Khullar V, Salvatore S.A medium-term analysis of the subjetive efficacy of treatment for women with detrusor instability and low bladder compliace. Br J Obster Gynaecol 1997; 104: 988-993.

17. Nilvebrant L, Hallén B, Larson G. Tolterodine - a new bladder selective muscarinic receptor antagonist: preclical pharmacological and clinical data. Life Sci 1997; 60: 1129-1136.